An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).

99%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

All-trans Retinoic Acid

Powder

DMSO 60 mg/mL

Ethanol 6 mg/mL

RAR ，RXR

Tretinoin prevents the cytotoxicity of H2O2 in cultured human mesangial cells by increasing both the catalase activity and the reduced glutathione content, which are dose- and time-dependent changes. Tretinoin-incubated mesangial cells leads to increased levels of catalase mRNA and gamma-glutamyl-cysteine synthetase (catalytic subunit) mRNA, the latter being the rate-limiting step in de novo reduced glutathione synthesis. Tretinoin upregulates matrix metalloproteinase-13 and matrix metalloproteinase-8 in human keloid-derived fibroblasts.

Tretinoin-treated old male Fischer 344 rats have 30% lower protein content in the renal cortex than control old rats, this effect may depend on the inhibition of the expression of tumor necrosis factor-beta1, a matrigenic cytokine, and osteopontin, a protein with cell adhesive and chemotactic properties. Tretinoin has the ability to prevent the major steroid-induced biomechanical changes in hairless mouse dermal connective tissue that contribute to atrophy. Tretinoin combined with imiquimod leads to faded tattoos and moderate clearance of pigment on histopathology in the guinea pig. Tretinoin increases fibroplastic proliferation in the Skin incisions were made in 45 CD-1 mice, but the production of collagen was diminished.

[1] Manzano VM, et al. J Pharmacol Exp Ther, 1999, 289(1), 123-132.
[2] Uchida G, et al. Exp Dermatol, 2003, 12 ,Suppl 2, 35-42.
[3] Schwartz E, et al. J Invest Dermatol, 1994, 102(2), 241-246.